Articles

At the European Hematology Association 2024 Annual Conference, researchers analyzed the relationship between hemoglobin and the quality of life of transfusion-dependent patients with lower-risk myelodysplastic syndromes receiving luspatercept or epoetin alfa. Read More ›

At the European Hematology Association 2024 Annual Conference, researchers presented the real-world dose escalation of luspatercept and its outcomes among patients with lower-risk myelodysplastic syndromes. Read More ›

At the European Hematology Association 2024 Annual Conference, researchers explored the emotional, physical, and financial burden experienced by patients with transfusion-dependent lower-risk myelodysplastic syndromes based in North America and Europe. Read More ›

Researchers presented a model to compare treatment outcomes for patients with lower-risk myelodysplastic syndromes who rely on red blood cell transfusions starting from first-line treatment initiation throughout their lifetime. Read More ›

At the ASCO 2024 Annual Meeting, researchers presented the differences in time toxicity among patients undergoing myelodysplastic syndromes/neoplasms with oral hypomethylating versus parenteral hypomethylating agents. Read More ›

At the ASCO 2024 Annual Meeting, researchers presented oral azacitidine’s safety and efficacy results in patients with low-/intermediate-risk myelodysplastic syndromes, as documented in the ASTREON trial. Read More ›

At the ASCO 2024 Annual Meeting, researchers summarized the most recent results from the phase 2 study of IMM01 in combination with azacitidine, a first-line treatment for adults with higher-risk myelodysplastic syndromes. Read More ›

At the 2024 ASCO Annual Meeting, researchers’ data from the COMMANDS trial, which evaluated the effectiveness of luspatercept in treating patients with transfusion-dependent, erythropoiesis-stimulating agent–naïve individuals with very low-, low-, or intermediate-risk myelodysplastic syndromes. Read More ›

Results of the phase 2 CLL2-BZAG trial indicated that MRD-guided triple combination of zanubrutinib, venetoclax, and obinutuzumab induced deep remissions in patients with R/R CLL including those previously treated with BTKi and/or venetoclax. Read More ›

Final data from the phase 3 MURANO trial demonstrated a significantly prolonged time to second progression-free survival event in the venetoclax/rituximab arm, with high response rates achieved even by patients who subsequently received retreatment or crossed over to venetoclax-based regimens or BTKi therapy. Read More ›